The Role of Mammographic Calcification in the Neoadjuvant Therapy of Breast Cancer Imaging Evaluation

Introduction Investigate the patterns of mammographically detected calcifications before and after neoadjuvant chemotherapy (NACT) to determine their value for efficacy evaluation and surgical decision making. Methods 187 patients with malignant mammographic calcifications were followed to record the appearances and changes in the calcifications and to analyze their responses to NACT. Results Patients with calcifications had higher rates of hormonal receptor (HR) positive tumors (74.3% versus 64.6%) and HER2 positive tumors (51.3% versus 33.4%, p = 0.004) and a similar pathologic complete response (pCR) rate compared to patients without calcifications (35.4% versus 29.8%). After NACT, the range of calcification decreased in 40% of patients, increased in 7.5% and remained stable in 52.5%; the calcification density decreased in 15% of patients, increased in 7.5% and remained stable in 77.5%; none of these change patterns were related to tumor response rate. No significant correlation was observed between the calcification appearance (morphology, distribution, range, diameter or density) and tumor subtypes or pCR rates. Among patients with malignant calcifications, 54 showed calcifications alone, 40 occurred with an architectural distortion (AD) and 93 with a mass. Calcifications were observed inside the tumor in 44% of patients and outside in 56%, with similar pCR rates and patterns of change. Conclusions Calcification appearance did not clearly change after NACT, and calcification patterns were not related to pCR rate, suggesting that mammogram may not accurate to evaluate tumor response changes. Microcalcifications visible after NACT is essential for determining the extent of excision, patients with calcifications that occurred outside of the mass still had the opportunity for breast conservation.

[1]  D. King,et al.  Mammography in the assessment of response to medical treatment of large primary breast cancer. , 1993, Clinical radiology.

[2]  S. Singletary,et al.  Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy , 2006, Annals of surgery.

[3]  K. Jung,et al.  Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. , 2011, The British journal of radiology.

[4]  G. Hortobagyi,et al.  Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[6]  G. Hortobagyi,et al.  Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. , 1988, Radiology.

[7]  Hans-Peter Sinn,et al.  International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G J Metzger,et al.  MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation , 2001, Journal of magnetic resonance imaging : JMRI.

[10]  J E Husband,et al.  Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. , 1996, Radiology.

[11]  C. Zuiani,et al.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.

[12]  W. Han,et al.  Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer Patients , 2013, Annals of Surgical Oncology.

[13]  L. Garfinkel,et al.  Twenty‐year follow‐up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project , 1997, CA: a cancer journal for clinicians.

[14]  L. Pusztai,et al.  Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. , 2001, American journal of surgery.

[15]  William E Gillanders,et al.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. , 2010, American journal of surgery.

[16]  L. Piña,et al.  Hallazgos mamográficos en las microcalcificaciones asociadas a cáncer de mama tras quimioterapia neoadyuvante , 2007 .

[17]  M. Dewhirst,et al.  Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.

[18]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[19]  Z. Shao,et al.  Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  G. MacGrogan,et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  G. Fuhrman,et al.  Neoadjuvant chemotherapy in the treatment of breast cancer. , 2013, The Surgical clinics of North America.

[22]  R. Poppiti,et al.  Mammographic Appearance of Microcalcifications: Can They Change after Neoadjuvant Chemotherapy? , 2006, The breast journal.

[23]  T. Julian,et al.  Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients , 2011, Annals of Surgical Oncology.

[24]  M. Boudeulle,et al.  Structure and composition of microcalcifications in benign and malignant lesions of the breast: study by light microscopy, transmission and scanning electron microscopy, microprobe analysis, and X-ray diffraction. , 1984, Human pathology.

[25]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[26]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Development of Malignant Breast Microcalcifications After Neoadjuvant Chemotherapy in Advanced Breast Cancer , 2004, The breast journal.

[28]  G. Hortobagyi,et al.  Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.

[29]  T. Hieken,et al.  Correlating sonography, mammography, and pathology in the assessment of breast cancer size. , 2001, American journal of surgery.

[30]  G. Hortobagyi,et al.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Singletary,et al.  Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy , 2006, Annals of Surgical Oncology.

[32]  Rebecca S Lewis,et al.  Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. , 2004, Radiology.

[33]  M. Brizzi,et al.  Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease , 2001, Breast Cancer Research and Treatment.

[34]  G. Hortobagyi Multidisciplinary management of advanced primary and metastatic breast cancer , 1994, Cancer.

[35]  Robert C. Frazier,et al.  Mammographic, pathologic, and treatment-related factors associated with local recurrence in patients with early-stage breast cancer treated with breast conserving therapy. , 1999, International journal of radiation oncology, biology, physics.

[36]  A. Vincent-Salomon,et al.  Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Ebbs,et al.  Disappearing microcalcification after neoadjuvant chemotherapy--a case report. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[38]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.